3i-backed Havea acquires ixX in Belgium
3i Group-backed (3i) Havea Group (Havea), a European specialist in natural health products, has acquired ixX pharma, a key Belgian player in food supplements.
Founded in 2005 by Danny Bral and René Zagers, ixX pharma is one of the leading independent players in the Belgian premium food supplements market based on its unique scientific approach and renowned products, including ImmunixX, J-ixX and PEA-ixX. Thanks to René Zagers and Danny Bral’s commitment, ixX pharma has developed a large range of products in segments such as immunity, vitamins & minerals, and pain relief. Brand awareness and recommendations by pharmacists have enabled ixX pharma to achieve a 14 per cent organic topline CAGR with cEUR12 million of revenue in 2020.
Aragan is Havea’s brand which specialises in the design and distribution in pharmacies of premium food supplements based on natural ingredients. The brand is mainly present in France and generates revenue of cEUR30 million.
By combining the expertise of Aragan in France and of ixX pharma in Belgium, Havea is supporting Aragan’s international growth and capitalising on the common DNA of the two brands, which is based on a scientific approach and the naturality of their products. The acquisition of ixX pharma also builds on Havea’s existing presence in Belgium, through Densmore & Vitavea.
The combined entity will enable Havea to accelerate its growth ambition for Aragan, which now has revenue approaching EUR50 million, through accelerated digitalisation and e-commerce, increasing “medicalisation” of the brand, and a complementary brand offering with enhanced innovation capabilities.
Havea will leverage the expertise of the ixX pharma team, based in Nieuwkerken-Waas – in particular, Danny Bral, head of scientific research, development and marketing, René Zagers, commercial partner of the pharmacists for 40 years and Peter Coussement, head of operations - to continue to develop the brand. The transaction is expected to close in mid-September 2021.
Bral and Zagers says: “We recently decided to start a new development phase for ixX pharma, by joining a partner capable of boosting the brand’s growth. We are convinced that by joining Havea, ixX pharma will keep its unique identity while benefiting from the platform Havea has built for its brands.”
Nicolas Brodetsky, CEO of Havea, says: “I am thrilled to welcome ixX pharma and its team to Havea and for Aragan and ixX pharma to join forces. Both brands share a very similar model based on pharmacists’ advice. The brand awareness and expertise of ixX pharma in the Belgian food supplements markets will enable Havea to become a key player in Belgium, by leveraging the common DNA of ixX pharma and Aragan.”
Rémi Carnimolla, 3i France Managing Partner, adds: “Only ten months after its last acquisition (of Calmosine), 3i is happy to support Havea with a new acquisition; the fifth acquisition in five years. The combination with ixX pharma is perfectly aligned with the group’s strategy of developing an international platform in the high growth, food supplements markets, particularly in the premium segment.”